Pharmacyclics shares plunge on NDA rejection

Shares of Pharmacyclics were hammered this morning after the company announced that the FDA had refused to accept its NDA for a new therapy to fight lung cancer that has spread to the brain. Pharmacyclics said that the agency had issued a "refuse to file" letter for Xcytrin, saying it was unable to review the clinical data on the therapy. The company says that it is reviewing the program.

"We will be evaluating our options with Xcytrin for the brain metastases indication and determine the best path forward," said Richard A. Miller, M.D., president and CEO of Pharmacyclics. "Beyond this indication, the clinical development program with Xcytrin continues on multiple fronts. Several ongoing trials are evaluating Xcytrin in non-small cell lung cancer and other cancers. We are also moving forward with several other novel compounds, which are in clinical and preclinical development."

- check out this press release
- read the AP report on Pharmacyclics

Related Articles:
Pharmacyclics shares plunge after Xcytrin flunks Phase III. Report
Pharmacyclics acquires cancer treatment candidates from Celera. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.